Online citations, reference lists, and bibliographies.

Inhibition Of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-associated Iris Neovascularization In A Nonhuman Primate.

Anthony P. Adamis, David T. Shima, Michael J. Tolentino, Evangelos S. Gragoudas, Napoleone Ferrara, Judah Folkman, Patricia A D'Amore, Joan W Miller
Published 1996 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To determine if the angiogenic peptide vascular endothelial growth factor (VEGF) is required for retinal ischemia-associated iris neovascularization in a nonhuman primate. METHODS Laser retinal vein occlusion was used to produce retinal ischemia in 16 eyes of eight animals (Macaca fascicularis). Eyes were randomized to treatment every other day with intravitreal injections of either a neutralizing anti-VEGF monoclonal antibody or a control monoclonal antibody of the same isotype. Serial iris fluorescein angiograms were assessed using a standardized grading system and masked readers. Retinal VEGF and placental growth factor expression were assessed by Northern blotting. The specificity of the antibodies was determined in capillary endothelial cell proliferation assays prior to intravitreal injection. RESULTS Zero of eight eyes receiving the neutralizing anti-VEGF antibodies developed iris neovascularization. Five of eight control antibody-treated eyes developed iris neovascularization. The difference was statistically significant (P = .03). Intravitreal antibody injection did not impair the ability of the ischemic retina to increase VEGF messenger RNA expression. The anti-VEGF antibodies specifically inhibited VEGF-driven capillary endothelial cell proliferation in vitro. CONCLUSION These data demonstrate that VEGF is required for iris neovascularization in an adult nonhuman primate eye. The inhibition of VEGF is a new potential therapeutic strategy for the treatment of ocular neovascularization.



This paper is referenced by
10.1007/s001250051240
A model system for the study of human retinal angiogenesis: activation of monocytes and endothelial cells and the association with the expression of the monocarboxylate transporter type 1 (MCT-1)
Rachel M. Knott (1999)
VEGF-induced corneal neovascularisation in a rabbit experimental model.
Laurențiu Coman (2010)
10.18388/abp.2000_3967
Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages.
Alicja Józkowicz (2000)
10.1007/s001250050747
The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas
T. Murata (1997)
10.22608/APO.2017500
Ophthalmic Application of Anti-VEGF Therapy.
Timothy Y Y Lai (2017)
10.4103/0301-4738.103782
Insulin-like growth factor binding protein-3 in preterm infants with retinopathy of prematurity
Manizheh Mostafa Gharehbaghi (2012)
10.1155/EDR.2003.287
Growth Factors in Proliferative Diabetic Retinopathy
Zia Ali Khan (2003)
10.1016/S0181-5512(08)70342-5
Utilisation des anti-VEGF dans la dégénérescence maculaire liée à l'âge
F. Fajnkuchen (2008)
10.1002/14651858.CD007325.pub3
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Tasanee Braithwaite (2014)
10.1097/IAE.0b013e318188501f
Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.
Ninel Z. Gregori (2008)
10.2337/diabetes.54.4.1141
Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor.
Corinna Lebherz (2005)
10.2337/db12-1744
Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop Novel Therapies for Diabetic Retinopathy
Paul M. Titchenell (2013)
10.1023/A:1006314501634
Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor
Zhenping Zhu (1999)
THE CLINICAL MANAGEMENT OF DIABETIC RETINOPATHY
Arthur D. Fu (2004)
Intravitreal bevacizumab: an analysis of the evidence
Derrick P Smit (2007)
10.1097/IAE.0b013e3181884ff4
Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
J. Fernando Arévalo (2008)
10.1177/2042018813512360
Anti-vascular endothelial growth factor therapy for diabetic macular edema
David S Boyer (2013)
10.1097/IIO.0b013e31802bd873
Antiangiogenic therapy in neovascular age-related macular degeneration.
Richard C. Lin (2007)
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).
Gerard Anthony Lutty (2006)
10.1007/s00417-011-1709-6
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization
Zhang Chao-ran (2011)
10.1007/s004170100365
Vascular plasticity – the role of the angiopoietins in modulating ocular angiogenesis
Antonia Maria Joussen (2001)
10.1155/2012/319728
Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
Ilias Zampros (2012)
10.3390/ijms150916936
Emodin-Loaded Magnesium Silicate Hollow Nanocarriers for Anti-Angiogenesis Treatment through Inhibiting VEGF
Hua Ren (2014)
Increased interleukin-6 in aqueous humor of neovascular glaucoma.
K H Chen (1999)
10.1007/s004170050360
Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate
Jing Zhao Cui (2000)
10.1001/archopht.122.12.1844
Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Arup Das (2004)
Vitrectomy with Internal Limiting Membrane Peeling in Acute Central Retinal Vein Occlusion Presenting with Low Vision
Siamak Moradian (2009)
VEGF and the quest for tumour angiogenesis factors
Melvin Greenblatt ()
10.1167/iovs.04-0052
Inhibition of oxygen-induced retinopathy in RTP801-deficient mice.
Anat Brafman (2004)
10.1056/nejmc063011
Ranibizumab in neovascular age-related macular degeneration
Kenneth T. Eng (2006)
10.1038/srep05272
Preliminary Study on Retinal Vascular and Oxygen-related Changes after Long-term Silicone Oil and Foldable Capsular Vitreous Body Tamponade
Wei Yang (2014)
10.1016/j.ohc.2006.05.005
Role of vascular endothelial growth factor in ocular angiogenesis.
Naveed Shams (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar